ClinicalTrials.gg
RecruitingNCT07188558PiNACLE-H2HUpdated Nov 4, 2026

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

A Phase 3 interventional study of rondecabtagene autoleucel and axicabtagene ciloleucel in Large B-cell Lymphoma, Lymphoma, B-Cell and Relapsed Non-Hodgkin Lymphoma, sponsored by Lyell Immunopharma, Inc.. Recruiting at 44 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lyell Immunopharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 4, 2026First sites in Australia and CanadaSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
38th of 963
400 · median 37
Started
2026
with 30 others
Phase 3
72 of 1,131
4 open now
Primary completion
2029-12
later than 188 of 216 live
Registered
1,103rd of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 38th largest by planned enrollment of the 963 interventional ones that give a count, is one of 31 that started in 2026, is one of 72 in phase 3, reaches primary completion later than 188 of the 216 other live ones, and was the 1,103rd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Read the detailed description

PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.

Patients will be randomized (1:1) before leukapheresis to receive either:

  • Ronde-cel; or
  • Investigator's choice of axi-cel or liso-cel

Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.

Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.

Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.

03

Conditions studied

  • Large B-cell Lymphoma
  • Lymphoma, B-Cell
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma Refractory/ Relapsed
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B Cell Lymphoma Relapsed

Keywords

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • CAR T-Cell Therapy
  • CD19
  • CD19/CD20
  • Large B-cell Lymphoma
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 400 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Lyell Immunopharma, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
  2. confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)

    • Diffuse large B-cell lymphoma (DLBCL)
    • Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
    • DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
    • High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
    • Primary mediastinal large B-cell lymphoma (PMBCL)
    • Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
  3. disease after anti-CD20 antibody and anthracycline-containing chemoimmunotherapy
  4. by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
  5. (ECOG) performance status 0 or 1
  6. Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

  1. Patients ineligible to receive CD19 CAR T-cell therapy
  2. Primary CNS lymphoma
  3. Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
  4. Patients with prior history of , other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
  5. Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
  6. Active disease requiring ongoing systemic therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Rondecabtagene autoleucel

    Biological: rondecabtagene autoleucel

  • Active comparator
    Investigator's Choice CD19

    axicabtagene ciloleucel, lisocabtagene maraleucel

    Biological: axicabtagene ciloleucel · Biological: lisocabtagene maraleucel

Interventions

  • Biologicalrondecabtagene autoleucel

    An autologous, dual-targeting CD19/20 CAR T-cell candidate.

    Also known as: LYL314

  • An autologous CD19 CAR T-cell therapy

    Also known as: Yescarta, axi-cel

  • An autologous CD19 CAR T-cell therapy

    Also known as: Breyanzi, liso-cel

07

What researchers measure

Primary outcomes

  1. Event free survival

    The time interval from treatment initiation until the occurrence of a specific event of interest.

    Time frame: 36 months

Secondary outcomes

  1. Overall Response Rate

    Best Overall Response per Lugano Criteria

    Time frame: 36 months

  2. Complete Response Rate

    Complete Response per Lugano Criteria

    Time frame: 36 months

  3. Progression Free Survial

    The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

    Time frame: 36 months

  4. Overall Survival

    The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive.

    Time frame: 6 years

  5. Incidence and severity adverse events

    To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities.

    Time frame: 36 months

08

Study locations

41 of 44 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 47 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 23, 2025
StartActual
Jan 12, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Jan 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added — first sites in Australia and Canada. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • MedStar Georgetown University Hospital · Washington D.C., United StatesNot yet recruiting→Recruiting
  • AdventHealth · Orlando, United StatesNot yet recruiting→Recruiting
  • Northwestern · Chicago, United StatesNot yet recruiting→Recruiting
  • University of Iowa · Iowa City, United StatesNot yet recruiting→Recruiting
  • Cleveland Clinical Taussig Cancer Center · Cleveland, United StatesNot yet recruiting→Recruiting
  • University of Texas Southwestern Medical Center · Fort Worth, United StatesNot yet recruiting→Recruiting
Show 8 added (5 United States, 2 Australia, 1 Canada)
  • Tufts Medical Center · Boston, United States
  • Atlantic Health · Morristown, United States
  • University of New Mexico Comprehensive Cancer Center · Albuquerque, United States
  • Virginia Commonwealth University-Massey Cancer Center · Richmond, United States
  • Medical College of Wisconsin · Milwaukee, United States
  • Townsville University Hospital · Douglas, Australia
  • The Alfred · Melbourne, Australia
  • Princess Margaret Cancer Centre · Toronto, Canada
Nov 4, 2026
Contact
Study contact changed: c•••@lyell.com · •••0000→c•••@lyell.com · •••0000. See the current contact
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    8 sites added — first sites in Australia and Canada. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • MedStar Georgetown University Hospital · Washington D.C., United StatesNot yet recruiting→Recruiting
    • AdventHealth · Orlando, United StatesNot yet recruiting→Recruiting
    • Northwestern · Chicago, United StatesNot yet recruiting→Recruiting
    • University of Iowa · Iowa City, United StatesNot yet recruiting→Recruiting
    • Cleveland Clinical Taussig Cancer Center · Cleveland, United StatesNot yet recruiting→Recruiting
    • University of Texas Southwestern Medical Center · Fort Worth, United StatesNot yet recruiting→Recruiting
    Show 8 added (5 United States, 2 Australia, 1 Canada)
    • Tufts Medical Center · Boston, United States
    • Atlantic Health · Morristown, United States
    • University of New Mexico Comprehensive Cancer Center · Albuquerque, United States
    • Virginia Commonwealth University-Massey Cancer Center · Richmond, United States
    • Medical College of Wisconsin · Milwaukee, United States
    • Townsville University Hospital · Douglas, Australia
    • The Alfred · Melbourne, Australia
    • Princess Margaret Cancer Centre · Toronto, Canada
    Contact Study contact changed: c•••@lyell.com · •••0000→c•••@lyell.com · •••0000. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07188558
Lead sponsor
Lyell Immunopharma, Inc.
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jan 12, 2026
Primary completion
Dec 2029 (estimated)
Completion
Jan 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

James Dean, MD, PhD
Contact
clinicaltrials@lyell.com
000-000-0000
Mary Lessig, MS
Contact
clinicaltrials@lyell.com
000-000-0000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion